Loading
companiesCompany
BeyondSpring Pharmaceuticals
BeyondSpring is a New York biotechnology company developing plinabulin, a microtubule-binding agent tested in phase 3 for chemotherapy-induced neutropenia and for non-small-cell lung cancer, which received a complete response letter from the FDA in 2021.
Also called: BeyondSpring Pharmaceuticals Inc.BeyondSpring
Overview
BeyondSpring Pharmaceuticals, listed on Nasdaq, develops plinabulin, a small molecule that binds tubulin and triggers dendritic cell maturation. It ran phase 3 trials of plinabulin to prevent chemotherapy-induced neutropenia (PROTECTIVE-1 and 2) and, with docetaxel, in previously treated non-small-cell lung cancer (DUBLIN-3); the FDA issued a complete response letter for the neutropenia indication in 2021 asking for a second trial. OnCo records it as a registry sponsor of phase 3 cancer trials.
Similar pages
- CompanySpectrum Pharmaceuticals
Shares Neutropenia, Non-small-cell lung cancer.